Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Dietary measures and parenteral glucose or glucagon
5 evidence topics · 5 sources
Diet, glucose infusion, glucose monitoring, and glucagon for insulinoma: ENETS guidance
Dietary measures, tube feeding, and intravenous glucose for insulinoma: clinical review
“Dietary/glucose: regular meals or snacks rich in slow carbohydrates, also ante noctem, are generally recommended (Fig. 3). The inclusion of a bedtime or late night meal is sufficient in most patients, but nocturnal tube feeding might be required to avoid nocturnal hypoglycemia in severely symptomatic patients. IV glucose administered via a central IV indwelling catheter might be needed for the control of severe recurrent hypoglycemia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Glucagon contraindication in insulinoma and other label limits: glucagon prescribing information
Continuous glucagon infusion for insulinoma and NICTH with liver metastases
“Three patients had an insulinoma and four had non-islet cell tumor hypoglycemia (NICTH) due to hepatocellular carcinoma, colon carcinoma, meningeal sarcoma, and hemangiopericytoma, respectively. All of the patients had liver metastases.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“All patients with insulinoma responded to glucagon with a rise in blood serum glucose levels, indicating adequate glycogen stores. The four patients with NICTH had mixed responses: in two patients, the response suggested that hypoglycemia was due to an insulin-like tumor product; glucose levels did not rise in the other two cases, indicating that hypoglycemia was due to poor hepatic glycogen reserve/liver failure. In all cases, a glycemic response to glucagon predicted good response to long term treatment with glucagon (0.06-0.3 mg/hour, via intravenous infusion pump).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Glucose, nutrition, and glucagon infusion for NICTH: clinical review
“Initial treatment of hypoglycemia is accomplished by oral glucose and/or iv glucose- or dextrose-containing fluids as necessary. In many cases, this suffices to avoid further hypoglycemia (47, 55, 61, 62).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, when prompt resection is not feasible, iv glucose or dextrose often does not suffice to prevent hypoglycemia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Continuous glucagon infusion can be successful if the patient has a positive response to a glucagon stimulation test, and parenteral nutrition may allow higher glucose delivery, but both are limited by the need for continuous iv infusion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, the use of partial parenteral nutrition or total parenteral nutrition is not a desirable long-term strategy given the necessity of long-term venous access with its inherent risks of complications and concomitant risks of bloodstream infections, liver toxicity, and electrolyte imbalances, not to mention cost (84).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote